Marshall Wace LLP Has $3.44 Million Stock Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Marshall Wace LLP grew its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 1,963.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 75,849 shares of the company's stock after acquiring an additional 72,174 shares during the period. Marshall Wace LLP owned 0.17% of Apogee Therapeutics worth $3,436,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of APGE. Barclays PLC raised its position in Apogee Therapeutics by 369.2% in the third quarter. Barclays PLC now owns 365,046 shares of the company's stock valued at $21,443,000 after purchasing an additional 287,243 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Apogee Therapeutics by 22.2% in the fourth quarter. SG Americas Securities LLC now owns 9,890 shares of the company's stock valued at $448,000 after buying an additional 1,796 shares during the period. Swiss National Bank raised its holdings in Apogee Therapeutics by 17.5% in the 4th quarter. Swiss National Bank now owns 44,300 shares of the company's stock valued at $2,007,000 after buying an additional 6,600 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Apogee Therapeutics by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company's stock worth $1,736,000 after buying an additional 1,212 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new stake in Apogee Therapeutics during the 4th quarter worth approximately $226,000. Institutional investors and hedge funds own 79.04% of the company's stock.

Wall Street Analyst Weigh In

APGE has been the subject of several analyst reports. Citigroup assumed coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $95.00 price target for the company. Wedbush reaffirmed an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Finally, Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $92.17.

Insider Buying and Selling at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 3,520 shares of the business's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total value of $143,228.80. Following the completion of the sale, the insider now directly owns 252,623 shares of the company's stock, valued at $10,279,229.87. The trade was a 1.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $40.58, for a total value of $608,700.00. Following the completion of the transaction, the chief executive officer now owns 1,302,987 shares in the company, valued at approximately $52,875,212.46. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 33,970 shares of company stock valued at $1,241,701. 36.10% of the stock is currently owned by company insiders.

Apogee Therapeutics Trading Down 0.3 %

APGE stock traded down $0.13 during midday trading on Thursday, hitting $39.12. The stock had a trading volume of 96,597 shares, compared to its average volume of 512,697. The firm has a market cap of $1.76 billion, a P/E ratio of -16.30 and a beta of 1.72. The business has a fifty day moving average price of $35.40 and a two-hundred day moving average price of $42.46. Apogee Therapeutics, Inc. has a 1-year low of $26.20 and a 1-year high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). On average, equities analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.